Alere Determine Combo HIV 1/2 Ag/Ab rapid test for HIV
Alere Australia has gained approval for the marketing in Australia of the Alere Determine Combo HIV 1/2 Ag/Ab rapid test for HIV. This marks the first approval for an innovative HIV assay to be included on the Australian Register of Therapeutic Goods (ARTG) for use in a point-of-care situation.
Marketing approval required lengthy scrutiny by the TGA of the scientific and clinical evidence supporting the test, including its accuracy when performed in near patient situations by healthcare professionals other than pathology laboratory scientists.
The point-of-care test offers significant benefits to patients and to healthcare workers in terms of convenience and rapid management of immediate clinical issues. It brings HIV testing technology right to the patient’s bedside.
Phone: 07 3363 7100
Lonza TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium
The products provide researchers and manufacturers with high-performance, scalable and...
Grace Bio-Labs protein microarray tools
Grace Bio-Labs' microarray substrates provide high binding capacity and enable high assay...
Siemens Healthineers 3gAllergy assay
Siemens Healthineers has expanded its 3gAllergy assay menu with nine additional component...
